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IL-37, a newly described member of the IL-1 family, functions as
a fundamental inhibitor of innate inflammation and immunity. In
the present study, we examined a role for IL-37 during experimen-
tal colitis. A transgenic mouse strain was generated to express
human IL-37 (hIL-37tg), and these mice were subjected to dextran
sulfate sodium (DSS)-induced colitis. Despite the presence of
a CMV promoter to drive expression of IL-37, mRNA transcripts
were not present in colons at the resting state. Expression was
observed only upon disruption of the epithelial barrier, with
a six- to sevenfold increase (P = 0.02) on days 3 and 5 after con-
tinuous exposure to DSS. During the development of colitis, clin-
ical disease scores were reduced by 50% (P < 0.001), and
histological indices of colitis were one-third less in hIL-37tg mice
compared with WT counterparts (P < 0.001). Reduced inflamma-
tion was associated with decreased leukocyte recruitment into the
colonic lamina propria. In addition, release of IL-1β and TNFα from
ex vivo colonic explant tissue was decreased 5- and 13-fold, re-
spectively, compared with WT (P £ 0.005), whereas IL-10 was in-
creased sixfold (P < 0.001). However, IL-10 was not required for
the anti-inflammatory effects of IL-37 because IL-10-receptor anti-
body blockade did not reverse IL-37-mediated protection. Mecha-
nistically, IL-37 originating from hematopoietic cells was sufficient
to exert anti-inflammatory effects because WT mice reconstituted
with hIL-37tg bonemarrowwere protected from colitis. Thus, IL-37
emerges as key modulator of intestinal inflammation.
cytokine | intestine | inflammatory bowel disease
Inflammatory bowel disease (IBD) results from environmentalfactors (e.g., bacterial antigens) triggering a dysregulated im-
mune response in genetically predisposed hosts. IBD is often
characterized by an imbalance between the effector and regula-
tory arms of intestinal immunity, with a preponderance of pro-
inflammatory cytokines (1). Although TNF blockade induces
clinical remission in 50–70% of patients with IBD (2), sustained
remission rates decrease after 1 y (3). Furthermore, the efficacy of
manipulating other cytokines (e.g., IL-6, IL-10, and IL-11) has
been limited (4, 5). Thus, alternative biological therapies that
target additional pathways of the chronic inflammatory cascade
should be evaluated. Tilting the balance toward the proregulatory
arm is an attractive strategy, yet systemic IL-10 administration
resulted in limited efficacy (6). Of note, although anti-in-
flammatory cytokines such as IL-10, IL-1Ra, and TGFβ are ele-
vated in IBD, chronic inflammation continues uncontrolled (7, 8).
Of the 11 members of the IL-1 family, 7 are agonists (IL-1α,
IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ) and 2 are nat-
urally occurring receptor antagonists (IL-1Ra and IL-36Ra). IL-
37b (formerly IL-1F7b) is the last member of the IL-1 family
without a well-defined function (9, 10). Different from most IL-1
family members, IL-37 has emerged as an anti-inflammatory
cytokine. At the present time, a mouse homolog has not been
identified; however, five splice variants of human IL-37 have
been described (IL-37a–f) (10–13). The IL-37a isoform has a
unique N terminus encoded by exon 3 (11), whereas the short
isoforms IL-37c, IL-37d, and IL-37e lack exon 4, exon 2, or both
exons, respectively. None of the N-terminal sequences encoded
by exon 1 contain a prodomain, and it remains unclear whether
IL-37 is processed by caspase-1 to an active form (10, 14). In fact,
multiple N termini have been reported upon expression of full-
length IL-37 in mammalian cells (14, 15). Although there are
reports that IL-37 binds to the IL-18 receptor α-chain without
signaling (14, 15), there is no evidence that IL-37 acts as a re-
ceptor antagonist for IL-18 (14, 16). In contrast to an extracel-
lular role for IL-37, w25% of LPS-induced endogenous IL-37
translocates to the nucleus (17).
The anti-inflammatory properties of IL-37 have been demon-
strated in vitro. Mouse RAWmacrophages transfected with IL-37
displayed markedly reduced levels of LPS-induced IL-1α, IL-6,
TNF, and CXCL2 (18, 19). Similar reductions in LPS- and IL-
1–stimulated cytokines were observed in human THP-1 macro-
phages and A549 epithelial cells. Furthermore, siRNA treatment
of these cell lines targeting endogenous IL-37 resulted in signifi-
cant increases in 13 proinflammatory cytokines, including IL-1α,
IL-1β, IL-6, TNFα, and GM-CSF. In addition, expression of IL-37
in THP-1 cells resulted in a marked reduction of several in-
tracellular kinases important for transducing proinflammatory
signals, such as focal adhesion kinase (FAK), STAT1, p38MAPK,
and c-jun (19). IL-37 is also inducible in human peripheral blood
mononuclear cells (17). Kumar and colleagues have identified IL-
37 protein expression in tonsils, skin, esophagus, placenta, and
melanoma as well as carcinomas of the breast, prostate, colon, and
lung, albeit at low levels (10, 14).
In the current study, we examined the role of IL-37 with a
transgenic mouse strain generated to express human IL-37 (hIL-
37tg) during acute dextran sulfate sodium (DSS)-induced colitis
(20). We determined expression of IL-37 with the onset of colonic
injury and the effect of IL-37 expression on clinical parameters
and histological indices of colitis. Furthermore, changes in leu-
kocyte recruitment and local cytokine production were assessed.
Last, we generated bone marrow (BM) chimeric mice to ascertain
whether myeloid-derived IL-37 was sufficient to exert anti-
inflammatory effects in vivo.
Results
Transgenic IL-37 Expression Protects Mice from Clinical Signs of
Colitis. To evaluate whether IL-37 might protect mice from in-
testinal inflammation, DSS or water vehicle was administered to
WT and hIL-37tg mice for 7 d. Body weights of mice that re-
ceived water vehicle remained stable during the 7-d period. By
contrast, WT mice given DSS lost over 12% more weight than
hIL-37tg mice did (83 ± 2% vs. 97 ± 4%, P < 0.01) (Fig. 1A). In
addition, the disease activity index (DAI), a composite score
comprising clinical signs of colitis (weight loss, stool consistency,
and bleeding), was significantly higher in WT mice compared
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with hIL-37tg mice that received DSS (10.6 ± 0.6% vs. 5 ± 0.5%,
P < 0.0001) (Fig. 1B).
Reduced colon length serves as a surrogate macroscopic
marker of colonic injury, and IL-37tg mice exposed to DSS dis-
play marked protection compared with WT counterparts (61 ± 2
mm vs. 45 ± 2 mm, P < 0.001) (Fig. 1 C and D). Thus, hIL-37tg
mice were protected from all clinical indices of DSS colitis.
Transgenic hIL-37 Expression Ameliorates Histological Indices of
Colitis. Colonic tissues from DSS-treated mice were examined
to determine whether clinical signs of colitis correlated with
histological severity. hIL-37tg mice exhibited decreased total
histological scores (2.4 ± 0.4% vs. 7 ± 0.6%, P < 0.001) and its
components, namely leukocyte infiltrates (1.4 ± 0.2% vs. 3.2 ±
0.3%, P < 0.001) and tissue injury (1.3 ± 0.2 vs. 3.3 ± 0.4, P <
0.001), compared with WT mice (Fig. 2 A and B). In addition,
there was a significant reduction in leukocyte infiltrates, preser-
vation of epithelial cell integrity, decreased edema, and reduced
hyperplasia of the colonic muscularis propria in hIL-37tg mice
(Fig. 2C). Thus, hIL-37 exerts a potent protective effect from
DSS-induced intestinal injury.
IL-37 Expression Is Inducible and Correlates with Intestinal Barrier
Breakdown. In mouse and human cell lines transfected with IL-
37, there is no detectable expression unless cells are stimulated
with LPS (17). To determine whether the breakdown of the in-
testinal barrier induces the expression of the IL-37 transgene,
colonic tissue was assessed for IL-37 mRNA transcripts after
exposure to DSS. Although baseline expression was minimal,
IL-37 expression progressively increased after DSS exposure,
reaching a fivefold increase by day 3, with peak levels on day 5
(sevenfold, P = 0.02) (Fig. 3A), coinciding with the onset of
histologically evident colitis (Fig. 3 B and C). Thereafter, levels
decreased. Thus, an insult such as chemical injury, which results
in epithelial breakdown and influx of bacterial antigens, was
required for the induction of IL-37.
IL-37 Suppresses Colonic TNF and IL-1β Production and Induces IL-10.
Endogenous IL-37 reduces the production of several proin-
flammatory cytokines in vitro and in vivo (19). To assess whether
IL-37 had a similar capacity to modulate cytokine production
within colonic tissues after DSS injury, we measured the cytokines
released from colonic explant cultures harvested at day 7 in the
indicated experimental cohorts. IL-37 suppressed release of TNFα
by 13-fold (P < 0.001) and IL-1β by 5-fold (P < 0.001), whereas
the expression of IL-17, IL-6, and CXCL1 (KC) were unaffected
(Fig. 4). The inhibition of TNFα and IL-1β was contrasted by
a sixfold increase of IL-10 (P < 0.001) (Fig. 4), compared with
production from DSS-treated WT colonic tissues. Thus, expres-
sion of IL-37 not only suppresses TNFα and IL-1β but also
induces IL-10, an effect that is unique to this in vivo model.
Decreased Leukocyte Recruitment to the Colonic Lamina Propria of
DSS-Treated IL-37tg Mice. We profiled the subsets of leukocytes
within the colonic lamina propria of WT and hIL-37tg mice via
flow cytometry. We observed an all-encompassing effect, with
a significant reduction of the absolute counts for all subsets eval-
uated (Fig. 5A). An increase in the percentage of CD11chigh
MHCII+ dendritic cells (Fig. 5B; P < 0.001), CD11clowMHCII+
macrophages (P = 0.05), Siglec-FhighGR1neg eosinophils (P <
0.001), and Siglec-FnegGR1high neutrophils (P < 0.001) was ob-
served in DSS-treated WT mice compared with vehicle-treated
mice (WT-H2O). However, transgenic expression of IL-37 uni-
formly reduced recruitment of all assessed leukocyte populations
(P # 0.05) to the colonic lamina propria.
Hematopoietic-Derived IL-37 Is Sufficient to Protect from DSS Colitis.
Steady-state levels of IL-37 mRNA in the peripheral blood and
lung tissues of hIL-37tg mice is low or absent, despite a consti-
tutively active CMV promoter (19), and this absence is also ob-
served in colonic tissues (Fig. 2). Because the transgene showed
no tissue-specific expression, we generated BM chimeric mice to
ascertain the contribution of hematopoietic- and stromal-derived
IL-37 on its protective effect during experimental colitis.
We first assessed crypt architecture and proliferation at dis-
crete intervals from 1 to 56 d postirradiation, before the in-
duction of DSS colitis. Colonic sections from irradiated and
nonirradiated mice were immunostained for Ki67. Compared
with controls, colonic sections from mice both 1 and 3 d post-
treatment displayed significant irradiation damage, as measured
Fig. 1. Reduced severity of DSS colitis in hIL-37tg mice. DSS or water vehicle
was administered to WT and IL-37tg mice ad libitum in drinking water for 7
d. (A) Weight change during treatment was expressed as percentage change
from day 0. (B) Clinical DAI (SI Methods). (C) Macroscopic images of colons
from indicated treatment cohorts. (D) Colon lengths were assessed at nec-
ropsy on day 7. Colon lengths were assessed at necropsy on day 7. Data are
expressed as mean ± SEM. (A) **P < 0.01, ***P < 0.001 vs. IL-37tg. (B) ***P <
0.001 vs. WT-H2O,
+++P < 0.001 vs. WT-DSS (n = 19–27 mice from four in-
dependent experiments).
Fig. 2. Amelioration of histological indices in hIL-37tg mice subjected to DSS
colitis. (A and B) Histological assessment of colitis severity demonstrated
amelioration of all assessed parameters in IL-37tg mice compared with WT
mice. Data are expressed as mean ± SEM. ***P < 0.001 vs. WT (n = 27 mice per
cohort from four independent experiments). (C) Representative micrograph
images of colons from indicated treatment cohorts. (Scale bars: 200 μm.)




























by a loss of Ki67+ crypt cells (day 1: 37.3 ± 2% vs. 22.6 ± 2.5%;
day 3: 37.3 ± 2% vs. 21.6 ± 2.7%, P = 0.002) (Fig. S1 A–D).
However, after 56 d of reconstitution, no gross morphologic
differences in colons were detected between irradiated and
nonirradiated mice (day 56: 37.3 ± 2% vs. 35.7 ± 2.8%, P = 0.4)
(Fig. S1 A and D).
To confirm BM reconstitution, CD45.1 C57BL6/J (WT) mice
were used as donors or recipients of hIL-37tg BM. WT mice
receiving hIL-37tg BM (IL-37tg–WT) were designated “hema-
topoietic,” whereas hIL-37tg mice receiving WT BM (WT–IL-
37tg) were termed “stromal.” To control for the effects of irra-
diation/reconstitution, two additional control groups were gen-
erated by transferring WT BM into WT recipients (WT-WT) and
hIL-37tg BM into hIL-37tg recipients (IL-37–Tg–IL-37tg). Flow
cytometry confirmed >95% reconstitution for all experimental
cohorts (Fig. 6A). At 8 wk after reconstitution, DSS colitis was
induced. WT mice that received WT BM (WT-WT) or IL-37tg
mice receiving WT BM (WT–IL-37tg) lost weight (83 ± 0.2%
and 80 ± 3%, respectively) and exhibited significantly higher
DAI scores (9 ± 1 and 10.8 ± 0.6) (Fig. 6 B and C), whereas
those that received hIL-37tg BM (IL-37tg–WT, hematopoietic)
had significant protection from weight loss (93 ± 1% vs. 83 ±
0.2% in WT/WT-DSS, P < 0.005) and each of the clinical in-
dices of colitis (5 ± 0.6% vs. 9 ± 0.9% in WT/WT-DSS, P <
0.001). Thus, hematopoietic-derived IL-37 mediates the pro-
tective properties of this cytokine in colitis. Whether this is the
mechanism of protection by IL-37 in native conditions where the
gene is not transgenically expressed remains to be elucidated.
Hematopoietic-Derived hIL-37–Mediated Protection in DSS Colitis Is
Associated with Decreased IL-1β and TNFα Release but Increased IL-
10.Given the improvement of all clinical parameters observed in
WT mice receiving hIL-37tg BM, we harvested their colons for
macroscopic evaluation at 7 d after continuous administration of
DSS. WT and IL-37tg recipients receiving WT BM exhibited
significantly decreased colon lengths compared with mice re-
ceiving water vehicle (WT-WT: 72.4 ± 2 mm vs. 58 ± 1.4 mm,
P < 0.001; WT–IL-37tg: 72.4 ± 2 mm vs. 54.7 ± 1.3 mm, P < 0.001).
In contrast, WT mice receiving IL-37tg BM (IL-37tg–WT–DSS)
were markedly protected from DSS-induced colonic shortening
(66.3 ± 1 mm) (Fig. 7A).
Histological scores for the severity of colitis paralleled the
above findings (WT/WT-DSS vs. IL-37tg–WT–DSS: 7.8 ± 1 vs.
2.5 ± 0.5, P < 0.001). No protection was observed in hIL-37tg
recipients receiving WT BM (WT–IL-37tg–DSS) with a score of
8.5 ± 0.8 (Fig. 7 B and C).
Cytokine release from colonic explant cultures were assessed
in BM chimeric mice. Just as in hIL-37tg mice, WT mice
reconstituted with hIL-37tg BM revealed significantly decreased
release of IL-1β and TNFα (P < 0.001), whereas IL-10 was ele-
vated fivefold (P < 0.05) (Fig. 7D). Thus, the key cell type that
protects from DSS injury in IL-37tg mice is within the hemato-
poietic, not the stromal, compartment.
An Anti–IL-10 Receptor-Blocking Antibody Does not Affect the
Protective Effect of hIL-37 in DSS Colitis. Because IL-10 up-regula-
tion is a hallmark of IL-37 protection in DSS colitis, we blocked
Fig. 4. Levels of colonic IL-10, TNFα, and IL-1β. Colonic tissue
explants were harvested at 7 d after continuous DSS exposure
and cultured ex vivo at 37 °C for 24 h. Secreted cytokines were
assayed from supernatants as described in Methods and
expressed as picogram of cytokine per milligram of tissue (pg/
μg). Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01
vs. WT-H2O vehicle,
++P < 0.001, +++P < 0.001 vs. WT-DSS (n =
19–27 mice from four independent experiments).
Fig. 3. Induction of IL-37 mRNA correlates with intestinal barrier breakdown.
(A) Time course of IL-37 mRNA transcripts within colonic tissues during DSS
colitis. (B) Colonic tissues from DSS-treated WT and hIL-37tg mice were har-
vested on indicated days, and the severity of colitis was assessed as described
inMethods. (C) Representative micrographs of the progression of colitis at the
indicated time points in WT and IL-37tg mice. Data are expressed as mean ±
SEM (n = 4 mice per time point from two independent experiments). *P <
0.05, ***P < 0.001 vs. day 0 (A) or WT (B). (Scale bars: 200 μm.)












































IL-10 signaling with a specific anti-IL10 receptor mAb (1B1.3a).
DSS was administered to WT and hIL-37tg mice receiving anti–
IL-10R, and a second cohort of each strain received isotype
control antibody. Administration of anti–IL-10R did not alter the
severity of colitis (DSS: hIL-37tg IgG vs. hIL-37tg anti–IL-10R;
weight loss P= 0.139; DAI P= 0.093). Thus, the protective effect
from IL-37 is not because of induction of IL-10 (Fig. S2).
Discussion
This study is a pivotal demonstration of the anti-inflammatory
effect for IL-37 on a well-studied model of intestinal in-
flammation. We used a strain of mice transgenic for human IL-
37 as previously described (19). We examined the timeline of
hIL-37 induction after DSS-induced colonic injury in hIL-37tg
mice because identification of the mouse ortholog through da-
tabase searches or homology has been unsuccessful. The se-
quence of the human gene might have diverged from the mouse
ortholog, or the mouse might have a functional homolog rather
than a sequence ortholog. As an example of the latter, IL-8 is
absent in mice and rats, which express a functional homolog:
CXCL1 (14). Like other members of the IL-1 family, IL-37
shows no species specificity, and transfection of human IL-37 in
mice exhibited the same properties as expression in human cells
(18). Furthermore, we observed improvement of the clinical
signs of colitis and amelioration of all histological indices in hIL-
37tg mice. BM chimeric mice proved that IL-37 in this model is
derived from hematopoietic cells and that this source was suffi-
cient in protecting from colitis by decreasing release of TNFα
and IL-1β.
Expression of IL-37 Is Inducible and Correlates with Intestinal Tissue
Damage. TLR ligands and IL-1β induce IL-37 in human periph-
eral blood mononuclear cells (19). However, despite a constitu-
tively active CMV promoter, basal expression of IL-37 in colonic
tissues remained low and transcripts increased significantly be-
tween the third and fifth day after DSS administration, co-
inciding with colitic injury. Similarly, in the mouse RAW and
human THP-1 macrophage cell lines transfected with the same
CMV promoter vector, low or absent constitutive IL-37 protein
was increased in a dose-dependent manner after LPS treatment
(19). Other stimuli that increased IL-37 include cytokines such as
IL-18, IFNγ, IL-1, and TNFα. Furthermore, it appears that IL-37
may amplify the anti-inflammatory properties of TGFβ because
IL-37 engages SMAD3, the main intracellular effector of TGFβ
(21). Because the mechanism of action of IL-37 is likely in-
tracellular, it is unlikely that exogenous administration of IL-37
will be protective in colitis.
IL-37 might prevent excessive inflammatory responses with-
out suppressing beneficial homeostatic intestinal inflammation,
which is necessary to combat infection. Perhaps the role of IL-37
in vivo is to assist in detaining the progression from regulated to
dysregulated inflammation, therefore limiting tissue damage.
Thus, disruption of intestinal epithelial integrity in vivo with the
Fig. 6. Hematopoietic-derived IL-37 protects mice from co-
litis. BM chimeric mice were generated after irradiation of WT
(CD45.1) or hIL-37tg(CD45.2) mice as described inMethods. (A)
Flow cytometry analyses of donor and recipient CD45+ sple-
nocytes demonstrated >95% reconstitution. DSS or water ve-
hicle was administered to indicated chimeric mice ad libitum in
drinking water for 7 d. (B) Weight changes during treatment
were expressed as percentage change from day 0. (C) Clinical
DAI (SI Methods). Data are expressed as mean ± SEM. **P <
0.01, ***P < 0.001 vs. WT/WT-DSS (n = 6–11 mice per strain
from two independent experiments).
Fig. 5. Effect of hIL-37tg expression on colonic leukocyte infiltrates. As-
sessment of colonic leukocyte populations from WT and IL-37tg mice after
DSS treatment. (A) Major leukocyte subsets were expressed as absolute
numbers. (B and C) Representative flow cytometry plots of dendritic cells
(CD11chigh/MHChigh), macrophages (CD11clow/MHCIIhigh), eosinophils (Siglec
Fhigh/GR1neg), and neutrophils (SiglecFneg/GR1high). Data are expressed as
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. WT-DSS (n = 6 mice per
strain from two independent experiments).




























resultant infiltration of bacterial antigens was necessary to trigger
an increase of IL-37 transcripts.
Hematopoietic-Derived hIL-37 Is Critical for Protection During
Experimental Colitis. Because the insertion of the IL-37 transgene
occurs at random, it was unknown whether protection from colitis
originates from BM-derived or stromal cells. This distinction might
have clinical implications: As with the development of non-
myeloablative approaches to achieve partial BM reconstitution
(22), subsets of cells engineered to overproduce IL-37 under in-
nocuous promoters could be exploited to control relapses of IBD.
Because leukocytes are naturally attracted to sites of inflammation,
delivery of IL-37 to effector sites could be greatly facilitated if
leukocytes were its main source. Although leukocytes are not the
sole source of IL-37, which is also expressed by colonic epithelium
(10, 14), in the present study, only BM-derived cells were sufficient
to afford protection and most likely by reducing the production
of proinflammatory cytokines. Whether this will be the case with
physiologic production in a nontransgenic, nonmanipulated system
remains to be determined. The expression of several endothelial ad-
hesion molecules [e.g., intercellular adhesion molecule 1 (ICAM-
1), vascular cell adhesion molecule 1 (VCAM-1), and mucosal
addressin cell adhesionmolecule (MAdCAM-1)] that mediate firm
adhesion and transmigration of leukocytes to sites of inflammation
are regulated by proinflammatory cytokines such as TNFα and IL-
1β (23). Thus, down-regulation of these cytokines might result in
decreased recruitment of leukocyte subsets into the inflamed colon.
In concert with this effect, hIL-37 expression resulted in decreased
recruitment of leukocytes of myeloid and lymphoid lineages.
IL-10 Receptor Blockade Fails to Attenuate Protective Effects of hIL-37
in DSS Colitis. A key finding from this study was the marked in-
duction of IL-10 in hIL-37tg mice. IL-10 is protective in colitis:
IL-10-deficient mice develop enterocolitis and colon cancer (24),
whereas reconstitution of IL-10−/− mice with WT BM prevents
and treats colitis (25). The observed induction of IL-10 by IL-37
appears to be a unique component of its effect in experimental
colitis, and it was likely that IL-37–induced IL-10 produced by
infiltrating leukocytes could be the critical mediator of pro-
tection from colitis. Nevertheless, this does not appear to be the
case because blockade of IL-10R did not reverse the protective
effect in hIL-37tg mice. Thus, although the induction of IL-10
does not appear to mediate the protective effect of IL-37, our
data agree with the existing data from clinical trials in IBD in
which dampening TNFα levels is more effective than supple-
menting IL-10. Although DSS-induced colitis is an acute chem-
ically induced model mediated by innate immune responses, its
pathogenesis is markedly different from human IBD, in which
adaptive immune responses predominate. Ongoing studies will
examine whether IL-37 plays a protective role in both the
CD45Rbhigh transfer model of colitis and the TNFΔARE model
of chronic ileitis.
An imbalance of pro- and anti-inflammatory mechanisms has
been demonstrated in IBD (26), and the therapeutic effect of
blocking proinflammatory or increasing anti-inflammatory cyto-
kines has been formally evaluated clinically. However, only the
former strategy has become standard of care for patients, after
reproducibly inducing and maintaining remission in both ulcera-
tive colitis and Crohn’s disease. It remains unclear whether the
failure of boosting anti-inflammatory mechanisms to restore ho-
meostasis could be at least in part because of suboptimal delivery
to the intestine. The transient induction of IL-37 suggests that it
may be an early checkpoint to prevent the perpetuation of in-
flammation that results in chronic inflammatory diseases. Thus,
for its further development as a therapeutic agent, a mechanism
that triggers and maintains its expression might be required. Given
its broad effect on multiple proinflammatory mechanisms, in-
duction of IL-37 might be that ideal therapeutic. Fiocchi proposed
a decade ago that manipulating physiologic regulatory mecha-
nisms through “an endogenous approach” might be the next
therapeutic frontier in IBD (27). Further understanding the
mechanisms of action of IL-37 and ways to up-regulate its ex-
pression during a disease flare might represent such novel strategy.
Materials and Methods
Mice. Transgenic mice expressing human IL-37 (i.e., hIL-37tg) have been
previously described (19). C57BL/6J (WT) and CD45.1 (B6.SJL-Ptprca Pepcb/
BoyJ) mice were purchased from the Jackson Laboratory and maintained
under specific-pathogen free conditions. Fecal samples were negative for
murine Helicobacter species, protozoa, and helminthes. The Institutional
Animal Care and Use Committee at the University of Colorado approved all
animal procedures.
Generation of BM Chimeric Mice. Recipient mice (6 wk old) were irradiated
with 1,100 rad, and BM cells (isolated from femur and tibia) were injected in
0.1-mL 0.9% sodium chloride i.v. via the retro-orbital plexus (50 × 106 BM cells
per mouse). Tetracycline (100 mg/L) was administered (i.p.) for 2 wk after BM
transplantation. Mice were housed for 8 wk before induction of DSS colitis.
To assess BM reconstitution, spleens were excised at necropsy followed by
flow cytometry expressing either CD45.1(A20) or CD45.2(104) (eBioscience).
Fig. 7. Effect of hematopoietic-derived IL-37 on colitis and cytokine pro-
duction. DSS or water vehicle was administered ad libitum in drinking water
for 7 d toWT, IL-37tg, and indicated BM chimeric mice. (A) Colon lengths were
assessed at necropsy on day 7. (B) Histological evaluation of colons was per-
formed as described. (C) Representative micrographs of colons of indicated BM
chimeric mice. (Scale bars: 200 μm.) (D) Ex vivo colonic tissue explants of in-
dicated BM chimeric mice treated with DSS were cultured at 37 °C for 24 h.
Data are expressed as mean ± SEM. (A) ***P < 0.001 vs. WT-H2O,
+++P < 0.001
vs. WT/WT-DSS. (B) ***P < 0.001 vs. WT/WT-DSS, +++P < 0.001 vs. IL-
37tg/WT-DSS. (D) *P < 0.05, **P < 0.001, IL-37tg/WT vs. WT/WT-DSS (n =
6–11 mice per cohort from two independent experiments).












































Induction of DSS Colitis. DSS (3% wt/vol, 36,000–50,000 kDa; MP Biomedicals)
was administered indrinkingwater ad libitum for 7 d. DSS solutionwas replaced
on day 3. Clinical signs of colitis (i.e., weight loss, stool consistency, and fecal
blood) were recorded daily. Upon necropsy, colonic lengths were measured.
Tissue Processing and Assessment of Colitis. Colons were excised, opened
longitudinally, and fixed in 10% buffered formalin. Then they were em-
bedded in paraffin, sectioned (3–5 μm), and stained with hematoxylin/eosin.
The severity of colitis was assessed by two pathologists (M.M. and P.J.)
blinded to the time point, strain, and treatment groups, as per published
methods (28, 29).
Real-Time RT-PCR. Total RNA was isolated from colon with the RNeasy Mini
Kit (Qiagen). RNA samples (0.5 μg) were reversed-transcribed into cDNA
with a high-capacity cDNA archive kit (Applied Biosystems), and real-time
RT-PCR was performed with an ABI Prism 7300. IL-37 and 18s TaqMan Gene
Expression Assays (Applied Biosystems) containing primers, and FAM dye-
labeled TaqMan MGB probes were used to quantify mRNA transcripts of
interest. A relative quantity (RQ) value (2−DDCt, where Ct is the threshold
cycle) was calculated for each sample by using ABI RQ software (Applied
Biosystems). RQ values were calculated as fold change in gene expression
relative to the control group.
Leukocyte Isolation. Lamina propria mononuclear cells were isolated as
previously described (30).
Flow Cytometry. Colonic lamina propria mononuclear cells were incubated
with fluorescently labeled antibodies against the following: Siglec-F(E50-
2440) (BD Biosciences); GR-1(RB6-8C5) or CD19(6D5) (Biolegend); MHCII (M5/
114.15.2), CD4(RM4-5), CD11b(M1/70), CD11c(N418), or F4/80(BM8) (eBio-
science); CD8(53-6.7) (Biolegend); or corresponding isotype controls. Cells
were fixed with 1% paraformaldehyde and assayed with a BD FACSCanto II
(BD Biosciences). Further analyses were performed with FlowJo software
(Tree Star Inc.).
Colonic Explant Cultures and Assessment of Cytokine Production. Colons were
excised, placed in cold PBS, and opened longitudinally. Then they were
washed in complete RPMI medium 1640 [10% FBS (vol/vol), 100 IU penicillin,
100 μg/mL streptomycin, and 2 mM L-glutamine], and a 5-mm2 piece of tissue
from midcolon was placed in 1 mL of complete RPMI medium 1640 (5% FBS).
Explants were cultured at 37 °C for 24 h. The supernatants were aspirated,
centrifuged at 18,000 × g for 10 min, and stored at −70 °C for subsequent
cytokine analysis with Multiplex mouse cytokine assay (Quansys). The
remaining colonic explant tissue was homogenized, and a Bradford protein
assay was performed. The concentration of secreted cytokines in the su-
pernatant was subsequently normalized to total tissue protein and ex-
pressed as picogram of cytokine per microgram of tissue.
IL-10 Receptor Immunoblockade. DSS was administered to 8-wk-old WT or hIL-
37tg mice for 7 d as described in Induction of DSS Colitis. One experimental
group from each strain simultaneously received 200 μg of anti–IL-10 receptor
mAb (1B1.3a; American Type Culture Collection) or isotype mAb i.p. on days
0, 3, and 5 during the DSS administration period. Clinical signs of colitis were
recorded daily. Then mice were killed, and tissues were harvested at day 7,
as described in Tissue Processing and Assessment of Colitis.
Statistical Analysis. Statistical analyses were performed with the two-tailed
Student’s t test or a one-way ANOVA followed by a Newman–Keuls post hoc
test. Data were expressed as mean ± SEM.
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